Quoin Pharmaceuticals sets up at-the-market ADS sales deal with Leerink Partners

Quoin Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel with its principal executive offices located in Ashburn, Virginia, entered into a sales agreement on November 4, 2026 with Leerink Partners LLC under which it may sell American Depositary Shares, each representing 35 ordinary shares, through Leerink Partners acting as agent.¹

Any sales under the agreement would qualify as an "at the market offering" under Rule 415(a)(4) of the Securities Act, including sales made directly on Nasdaq or other trading markets for the company's ADSs.¹ Leerink Partners agreed to use commercially reasonable efforts, consistent with its normal trading and sales practices, to place all ADSs the company requests to sell.¹

Leerink Partners is entitled to compensation equal to 3.0% of the gross proceeds from ADSs sold under the agreement.¹ Either party may suspend the offering upon proper notice, and each has the right to terminate the agreement at its sole discretion with written notice as specified in the agreement.¹

Leerink Partners and its affiliates have previously provided, and may in the future provide, investment banking and other financial services to the company for customary fees.¹

The ADSs will be offered under the company's Form S-3 registration statement, originally filed October 28, 2026 and declared effective November 4, 2026, along with a base prospectus and a prospectus supplement dated the same day and filed under Rule 424(b)(5).¹

Meitar Law Offices, the company's Israeli counsel, issued a legal opinion on the validity of the ordinary shares underlying the ADSs, filed as an exhibit to the report.¹ The filing was signed by Dr. Michael Myers, Chief Executive Officer, on November 4, 2026.¹